Online inquiry

IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8894MR)

This product GTTS-WQ8894MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IGHE gene. The antibody can be applied in Chronic idiopathic urticaria research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NC_000014.9
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3497
UniProt ID P01854
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8894MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7880MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ8960MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ15806MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA XmAb14045
GTTS-WQ10738MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA M-281
GTTS-WQ10946MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MBG-453
GTTS-WQ9901MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA KB-003
GTTS-WQ13569MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PRX-302
GTTS-WQ8735MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA HuPRO-140
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW